Surrey Heartlands

Joint Formulary & PAD

Carbocisteine - Reduction of sputum viscosity

You are here : Home > Formulary Search > Carbocisteine - Reduction of sputum viscosity

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Capsules
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
Important
Preferred
Do not use in patients with active peptic ulcer disease or risk of GI bleeding.
 

Status 2

Green (see narrative)
Formulations :
  • Sachets (oral solution)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
Important
Reserve for patients with swallowing difficulties (aged 15 years and over)
 

Status 3

Green (see narrative)
Formulations :
  • Oral solution
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
Important
Reserve for use in children below the age of 15 years.

Documentation

Guidelines (Local)
Mucolytics prescribing advice for Primary Care - Apr 24

PAD Profile

ChemicalSubstance :
Carbocisteine
Indication :
Reduction of sputum viscosity
Group Name :
Keywords :
mucolytics, excessive mucous production, COPD, Bronchiectasis
Brand Names Include :
Mucodyne
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Reduction of sputum viscosity
Supporting Documents :
1
Traffic Light Entries :
3

Other Indications

Below are listed other indications that Carbocisteine is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Reduction of sputum viscosity.

Committee Recommendations (2)

03 Apr 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Area Prescribing Committee approved the Primary Care guidance for prescribing oral mucolytics to reduce sputum viscosity.

Carbocisteine should be prescribed generically.

Refer to the guidance for full details of product choice in adults, children and patients with swallowing difficulties.

03 May 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
GENERIC Carbocisteine has been considered by the PCN and has been assigned a GREEN traffic light status.

NOTE - the branded product, Mucodyne, was considered BLACK at the PCN in May 2017.